Journal Article

<i>Helicobacter pylori:</i> Consensus and Controversy

Larry J. Strausbaugh, Douglas J. Passaro, E. Julia Chosy and Julie Parsonnet

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 35, issue 3, pages 298-304
Published in print August 2002 | ISSN: 1058-4838
Published online August 2002 | e-ISSN: 1537-6591 | DOI:
Helicobacter pylori: Consensus and Controversy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Helicobacter pylori is uniquely adapted to colonize the human stomach. Infection leads to a range of subclinical and clinical outcomes that depend on properties of the infecting strain, the host, and the environment. Eradication therapy is indicated for infected persons who develop peptic ulcer disease or gastric lymphoma or who are beginning long-term treatment with nonsteroidal anti-inflammatory drugs. However, treatment may worsen gastroesophageal reflux disease and increase the risk of esophageal cancer. H. pylori infections can be diagnosed noninvasively and can be eradicated with ∼85% success by a variety of multidrug, 7–14-day regimens. Unfortunately, antibiotic resistance is affecting treatment effectiveness in the United States and abroad. A more complete understanding of the variation in H. pylori pathogenesis should lead to clearer recommendations about treatment for infected persons who have neither peptic ulcer disease nor gastric lymphoma.>

Journal Article.  4535 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.